EL — Annual 2026 Financial Report Analysis

Overview

The Estée Lauder Companies returned to sales growth in fiscal 2026 (the year from July 1, 2025 to June 30, 2026) after a difficult fiscal 2025. Net sales rose 5% to $15.05 billion, or 3% on an organic basis — organic growth strips out currency movements and acquisitions to show underlying demand. The company swung to a GAAP net profit of $182 million ($0.50 per diluted share) from a $1.13 billion loss ($3.15 per share) a year earlier.

That GAAP swing mostly reflects what did not happen this year: fiscal 2025 carried $1.29 billion of write-downs on the TOM FORD, Too Faced and Dr.Jart+ brands plus a $159 million talc litigation charge. The adjusted figures exclude restructuring, impairments and litigation settlements, and give a cleaner read: adjusted operating margin rose to 11.2% from 8.0%, and adjusted EPS rose 66% to $2.51. The main driver was cost cutting under the company's Profit Recovery and Growth Plan (PRGP), not sales growth.

Key Figures

n/m = not meaningful (a change from a loss to a profit). Adjusted figures are the company's non-GAAP measures; free cash flow is operating cash flow minus capital spending.

Sales: Growth Led by China, Travel Retail and Fragrance

All four regions grew on an organic basis, but the growth was concentrated:

The 10-K says higher sales in Mainland China and travel retail (duty-free shops at airports and other travel hubs) together added about $531 million — most of the year's $723 million increase. Travel retail benefited from Korean and Hong Kong duty-free operators shifting toward "more profitable duty-free business models, which helped reduce discounting," and from better traffic in Hainan. The Americas grew only 1%. In both the Americas and EUKEM, the 10-K shows volume up 4% offset by a 3-point drag from pricing and mix — meaning a larger share of what was sold came from lower-priced products. EUKEM's 6% reported growth was mostly currency: 5 points came from a weaker dollar.

By category, fragrance was the standout, up 10% organically to $2.78 billion, led by Le Labo, TOM FORD and KILIAN PARIS. Skin care, the largest category at $7.34 billion, grew 4% organically on La Mer, The Ordinary and the Estée Lauder brand. Makeup was flat at $4.28 billion — M·A·C's launch in US Sephora locations offset declines at Bobbi Brown and Too Faced — and the category posted an adjusted operating loss as the company increased marketing spend. Hair care fell 1% organically on continued weakness at Aveda.

The year ended with momentum: fourth-quarter (April–June 2026) organic sales rose 5%, including a return to growth in North America. That quarter included an $18 million one-time benefit from releasing unused gift-card liabilities, and the Middle East conflict reduced fourth-quarter sales growth by about 1 point.

Profitability: Cost Cuts Did Most of the Work

Gross margin (the share of sales left after the cost of making the products) rose 150 basis points (1.5 percentage points) to 75.5%. The company attributes this to PRGP savings — "a more competitive approach to procurement," expense optimization and lower write-offs of excess and obsolete stock — partly offset by inflation and tariffs. Incremental US tariffs cost $102 million gross for the year; the company recovered $38 million of that in the fourth quarter through refunds of tariffs paid under the International Emergency Economic Powers Act (IEEPA).

The PRGP restructuring program is now fully approved: roughly 10,000 net job cuts, expected annual gross benefits of about $1.2 billion, and total charges expected to land "slightly above" the top of the $1.5–$1.7 billion range. Restructuring charges were $813 million in fiscal 2026, which is the main reason GAAP operating margin (5.2%) sits so far below the adjusted figure (11.2%). The company also booked an $84 million charge, net of insurance, to settle a securities class action.

Below the operating line, the GAAP effective tax rate — the share of pre-tax profit paid in tax — was 64.8%, which the company attributes to its geographic mix of earnings (including new valuation allowances on some foreign deferred tax assets), recent US tax legislation and transfer-pricing matters. That is why $517 million of pre-tax earnings became only $182 million of net earnings. The adjusted tax rate was 35.7%.

Cash generation improved sharply. Operating cash flow rose 39% to $1.77 billion and capital spending fell to $457 million from $602 million, lifting free cash flow to $1.32 billion from $0.67 billion. Cash ended the year at $3.50 billion, after $508 million of dividends and $300 million of deferred payments for the TOM FORD acquisition.

Takeaway: Estée Lauder's recovery so far is mostly a cost story. Organic sales grew only 3%, and outside Mainland China and Asia/Pacific (which houses travel retail — the business whose collapse caused the downturn) organic growth was about 1%. Adjusted operating margin rose 3.2 points because restructuring cut costs, not because demand recovered broadly. Fiscal 2027 has to show the sales side improving, especially in the Americas, because much of the restructuring savings is now already in the numbers.

Outlook for Fiscal 2027 (July 2026 – June 2027)

Management expects growth to be stronger in the first half, helped by earlier product launches, improving travel retail trends and a low travel retail comparison, with fragrance and skin care continuing to grow and makeup returning to growth for the full year. It expects operating cash flow to fall because of higher restructuring payments and more working capital. The outlook assumes no deterioration in geopolitics, tariffs or consumer sentiment.

Our read: The margin guidance looks achievable — the company says a "vast majority" of the full run-rate PRGP savings will be realized in fiscal 2027, and it delivered the restructuring at the high end of its own targets. The sales guidance is the harder part. Reaching the top of the 3%–5% range needs makeup and the Americas to contribute, and those were two of the weakest parts of fiscal 2026. The first-quarter report (quarter ending September 30, 2026) is the first real test: if organic growth holds near the fourth quarter's 5% with North America still growing, the recovery is broadening; if growth again depends mostly on China and travel retail, it is not.